Genomics firm Helicos gets delisted

The Cambridge, MA based genomics company Helicos Biosciences has been delisted from the NASDAQ. The company received a delisting notice in April. Shortly after, Helicos cut its work force in half, laying off 40 people to focus on its diagnostics business, but in the months since it has been unable to goose its stock above the $1 mark. Article

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.